Dual targeting of human epidermal growth factor receptor 2 (HER2) in neoadjuvant trials for operable HER2 positive (HER2+) disease Journal Article


Authors: Jhaveri, K.; Dang, C.
Article Title: Dual targeting of human epidermal growth factor receptor 2 (HER2) in neoadjuvant trials for operable HER2 positive (HER2+) disease
Abstract: The neoadjuvant strategy, initially developed to render primary inoperable tumors operable, is now increasingly being utilized for patients with triple-negative and HER2 positive breast cancer in clinical trials in order to assess for response and resistance with the incorporation of tissue biopsy studies. Pathological complete response (pCR) has been accepted as a primary endpoint in a number of neoadjuvant trials for operable HER2+ disease. This article provides a comprehensive summary of the knowledge gained from neoadjuvant trials conducted with HER2 directed agents to date, focuses on the concept of dual blockade of HER2, highlights the importance of predictive biomarkers, and finally puts them into perspective with current treatment recommendations and future research and trends. © 2013 Springer Science+Business Media New York.
Keywords: breast cancer; clinical trials; neoadjuvant; pcr; her2 positive; dual blockade
Journal Title: Current Breast Cancer Reports
Volume: 5
Issue: 4
ISSN: 1943-4588
Publisher: Springer  
Date Published: 2013-12-01
Start Page: 321
End Page: 330
Language: English
DOI: 10.1007/s12609-013-0124-x
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 3 February 2014 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Chau Dang
    160 Dang